Lilly India Wins CDSCO Nod for Donanemab in Alzheimer's Care

Eli Lilly and Company (India) Pvt. Ltd. has obtained CDSCO marketing approval for donanemab. The medication provides an alternative therapy to adults experiencing early symptomatic Alzheimer disease.

Mild cognitive impairment (MCI) and mild dementia stage patients are also treatable as long as the amyloid pathology is verified.

Amyloid is a naturally occurring protein. When it forms lumps in the form of plaques, it interferes with memory and thought. Donanemab finds its way to such plaques and assists the body to eliminate them.

Also Read: The Future of Genomic Sequencing: Trends That Will Define the Next Decade

This delays the deterioration that attacks the daily functions like the recalling of dates, handling finances, cooking, and independence. Winselow Tucker, President and General Manager, Lilly India, said the approval of donanemab is a great milestone in our mission of meeting the urgent needs of people living with Alzheimer disease in India.

Providing a new treatment that removes amyloid plaques and delays the cognitive loss, we will provide patients and their families with more time and a higher quality of life. This highlights the efforts of Lilly to provide innovative therapies in India to the people who require most. Alzheimer is the most prevalent dementia cause in the world, but it is poorly diagnosed. The fast aging population of India is projected to push the number of dementia cases to over 8 million by the year 2030 with the majority being Alzheimer.

The entry of donanemab shows the increased attention to early diagnosis and therapy. The treatment is administered as an intravenous infusion every four weeks 700 mg during the initial three treatments, followed by 1400 mg. Some of the side effects that are very disastrous are ARIA and infusion-related reactions.